Active-ingredient Dossier
Tadalafil
Active-ingredient Dossier for Tadalafil (phosphodiesterase-5 inhibitor). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.
- Brand: OPSYNVI
- Brand: TADALACCORD
- Brand: TADALCA
- Brand: TADALIS
- Brand: CIALIS
- Brand: ADCIRCA
- Therapeutic area: Reproductive Health
- Therapeutic area: Cardiology
- Therapeutic area: Urology
What is
Tadalafil Tadalafil is a phosphodiesterase-5 inhibitor.
Australian brands containing
Tadalafil — TADALACCORD — TADALCA — TADALIS — CIALIS — ADCIRCA — ADIR — ADIRA — ADIRAMED — APO-Tadalafil — CIDALA — CILATIL — TADACIP
Therapeutic areas
Tadalafil is registered in urology (18 brands) and cardiology (5 brands).
Sponsor landscape
The ingredient is marketed by eleven sponsors: Dr Reddys Laboratories, AdiraMedica, Arrotex Pharmaceuticals, Eli Lilly, Accord Healthcare, and Alphapharm, among others.
PBS and regulatory activity
Three brands containing tadalafil have PBS-listed items, with the latest PBS schedule date of 1 May 2026. The latest PBAC outcome was recorded on 1 March 2024, and the latest AusPAR was published on 16 May 2013.